Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Hoffmann

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Cancers|April 12, 2022
Unmet Needs and Perspectives in Oral Cancer PreventionJebrane Bouaoud, Paolo Bossi, Moshe Elkabets, et al.
Head & Neck|April 10, 2024
International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancersXavier Liem, Thierry de Baère, Omar I Vivar, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2019
Immune gene expression in head and neck squamous cell carcinoma patientsCharlotte Lecerf, Maud Kamal, Sophie Vacher, et al.
Future Oncology (London, England)|May 5, 2025
Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCCChristophe Le Tourneau, Zoltán Takácsi-Nagy, Sandra Nuyts, et al.
Clinical & Translational Immunology|May 16, 2022
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccinationRodrigo Nalio Ramos, Caroline Tosch, Fiorella Kotsias, et al.
Nature Communications|May 12, 2025
Transcriptome analysis of archived tumors by Visium, GeoMx DSP, and Chromium reveals patient heterogeneityYixing Dong, Chiara Saglietti, Quentin Bayard, et al.
Scientific Reports|December 19, 2023
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activityGrégoire Marret, Stéphane Temam, Maud Kamal, et al.
Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.
JAMA Otolaryngology-- Head & Neck Surgery|January 29, 2026
Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical TrialChristophe Le Tourneau, Xavier Liem, France Nguyen, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancers|April 12, 2022
Unmet Needs and Perspectives in Oral Cancer PreventionJebrane Bouaoud, Paolo Bossi, Moshe Elkabets, et al.
Head & Neck|April 10, 2024
International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancersXavier Liem, Thierry de Baère, Omar I Vivar, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2019
Immune gene expression in head and neck squamous cell carcinoma patientsCharlotte Lecerf, Maud Kamal, Sophie Vacher, et al.
Future Oncology (London, England)|May 5, 2025
Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCCChristophe Le Tourneau, Zoltán Takácsi-Nagy, Sandra Nuyts, et al.
Clinical & Translational Immunology|May 16, 2022
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccinationRodrigo Nalio Ramos, Caroline Tosch, Fiorella Kotsias, et al.
Nature Communications|May 12, 2025
Transcriptome analysis of archived tumors by Visium, GeoMx DSP, and Chromium reveals patient heterogeneityYixing Dong, Chiara Saglietti, Quentin Bayard, et al.
Scientific Reports|December 19, 2023
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activityGrégoire Marret, Stéphane Temam, Maud Kamal, et al.
Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.
JAMA Otolaryngology-- Head & Neck Surgery|January 29, 2026
Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer: A Phase 1 Dose-Expansion Nonrandomized Clinical TrialChristophe Le Tourneau, Xavier Liem, France Nguyen, et al.
Pageof 4